Spiny follicular hyperkeratosis eruption: a new cutaneous adverse effect of sorafenib.
Franck
Nathalie
N
Barete
Stéphane
S
Moguelet
Philippe
P
Blanchet
Benoît
B
Carlotti
Agnès
A
Ropert
Stanislas
S
Avril
Marie Françoise
MF
Francès
Camille
C
Billemont
Bertrand
B
Goldwasser
François
F
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D001557:Benzenesulfonates / Q000008:administration & dosage / Q000009:adverse effects*; D003875:Drug Eruptions / Q000209:etiology*; D005260:Female; D005499:Folliculitis / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D007642:Keratosis / Q000139:chemically induced* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011494:Protein Kinases / Q000187:drug effects; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects*; D012867:Skin / Q000187:drug effects* / Q000473:pathology; D000077157:Sorafenib
D020533:Angiogenesis Inhibitors; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib; D011494:Protein Kinases